date of comment,main comment,comment,depth,PTR Sentiment,Flair Outlook,Flair Sentiment
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","Sorry NVO team, I invested in NVO. I would like to think if it were not for me, today’s news would have made a huge pop in stock price versus being down.",0,0.545,NEGATIVE,1.0
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","It will once market opens.Or maybe it doesnt, Tesla missed every metric and went up 30% so...",1,0.532,NEGATIVE,0.999
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",The reason for the drop is that sales are slightly down from last quarter. Sales were 65.9B kroner last quarter compared to 65.3B this quarter. YoY is a big increase but production has flatlined sales.,2,0.63,NEGATIVE,0.996
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","You might be right, but doesnt warrant a fall, as they have been acquiring what they can to ramp up production.",3,0.503,NEGATIVE,0.998
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Didn’t they cut prices in home market or maybe thats after reporting period,3,0.55,NEGATIVE,1.0
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Elon said AI. That’s all it takes.,2,0.711,POSITIVE,0.573
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Danish market is open.,2,0.595,POSITIVE,0.966
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",A/S shares are only on NYSE,3,0.515,NEGATIVE,1.0
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","I haven't added shares for the same reason I didn't invest in LLY 5 years ago, I don't understand the business anywhere near well enough.How do I know I'm not investing into PFE in the late 90s, on the back of incredible stock returns, only to get a stock that went nowhere for 25 years?",0,0.57,NEGATIVE,0.995
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","Simple, had you invested in LLY 5 years ago u'd be 600% up.But in 5 years you can bump this thread.",1,0.522,POSITIVE,0.711
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","Go listen to ""The Ozempic Economy"" by today, explained, if you're interested. They did some good reporting on the extent of their expansion and the wider implications of these drugs. That episode was actually what piqued my interest in them.Their revenue and profits are growing rapidly as new capacity comes online, the company has continuously done ever larger stock buybacks for decades, and they pay a healthy dividend. It's seen steady constant growth since it came onto the US markets, and that won't change anytime soon. If anything, it will just pick up steam as people realize what's actually going on here.",1,0.551,POSITIVE,0.99
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Denmark is one of the few EU countries operating at a surplus in relation to GDP thanks to Novo. The other two are Ireland (corporate tax haven) and Cyprus (Russian money laundering).,2,0.528,POSITIVE,0.966
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",And for some reason the stock keeps dropping.,0,0.603,NEGATIVE,1.0
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",,1,,,
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",It’s doing pretty well now. That comment was from 24 days ago.,2,0.529,POSITIVE,0.697
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",As soon as we get good oral GLP-1 drugs all these injectables are going away,0,0.517,NEGATIVE,0.999
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Yes and Novo is developing it.,1,0.513,POSITIVE,0.998
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","They have an inferior oral. The best in class is on the way which will be years ahead of all the copy cats coming out. Once the new oral is approved, supply chain issues will no longer be an issue.",2,0.551,POSITIVE,0.999
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","NVO is first to market and expanding capacity faster than competitors. The market for these drugs isn't getting saturated anytime soon, either. This is at the intersection of weight loss and healthcare, which are both massive industries, and everyone in the market will be able to benefit to some extant, but NVO will do better than others.",3,0.541,POSITIVE,0.937
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Which best in class are you talking about? You are not mentioning any company or product. Show me something.https://www.fiercebiotech.com/biotech/another-day-another-win-novo-obesity-early-oral-med-beats-wegovyhttps://www.biopharmadive.com/news/novo-nordisk-obesity-pill-amycretin-wegovy/709608/,3,0.536,NEGATIVE,0.949
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",NVO Amycretin. Yes the links you provided have the right info. The problem with Wegovy is that the drug is not the supply constraint but the injectables. With Amycretin you get better results than Wegovy and you eliminate the supply constraint. Wegovy is the holding place for Amycretin. From preliminary test results this new pill appears to be best in class,4,0.531,POSITIVE,0.936
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Amycretin is Novo. Did you mix it up with something else?,5,0.501,NEGATIVE,1.0
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",NVO is the ticker on the NYSE,6,0.507,NEGATIVE,0.983
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",,7,,,
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",,8,,,
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",,9,,,
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Yes? Novo=NVO,5,0.5,POSITIVE,0.908
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Peptides function much differently than small molecules which tend to have lots of off target effects based on their drug profiles,1,0.515,NEGATIVE,0.982
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Once a week injections are of little consequence. I take 6 a day currently.,1,0.528,NEGATIVE,0.847
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",I'm not sure they will. I would guess that patient compliance is higher when you don't have to remember to take it daily. I'd personally prefer an auto injector once a week over a pill I have to remember every day.,1,0.539,NEGATIVE,0.959
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Statements like 'this will be europe's nvidia by 2026' is exactly what keeps me away from stocks like this.,0,0.539,POSITIVE,0.551
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",ull likely come back when its double what it is,1,0.515,NEGATIVE,0.501
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","Entire sectors and industries are about to crumble, as nobody is hungry anymore, and we re here cheering",0,0.503,POSITIVE,0.99
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","Nobody is hungry anymoreYeah, okay…",1,0.5,POSITIVE,0.647
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Did Lilly lower their price?,0,0.478,NEGATIVE,0.992
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Did Lilly lower their price?,1,0.478,NEGATIVE,0.992
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Are there any downsides of Ozempic? That's the only thing that can kill it,0,0.498,NEGATIVE,0.929
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",Some gastroparesis symptoms. Queasiness after eating high carb meals.,1,0.508,NEGATIVE,0.999
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?",They appear to be fairly mild compared to Orlistat.,1,0.504,NEGATIVE,0.945
,"Novo brought in 65.3 billion Danish kroner ($9.4 billion) in net sales during the first three months of 2024, up around 22% on the same period last year. The company reported net profit of 25.4 billion Danish kroner ($3.65 billion), a 28% year-on-year rise. Novo’s diluted earnings per share of 5.68 Danish kroner ($0.82) mark a 29% increase from the 63 cents per share reported this time last year. Both earnings per share and revenue comfortably beat analyst estimates of 75 cents per share and $9.1 billion, respectively, according to FactSet. Novo raised its outlook for 2024, expecting sales growth of 19% to 27% and operating profit growth between 22% and 30%, ranges that are both one percentage point higher than previous forecasts. Novo Nordisk shares were down nearly 2% during trading in Copenhagen on Wednesday morning. https://www.forbes.com/sites/roberthart/2024/05/02/ozempic-maker-novo-nordisk-beats-profit-forecasts-amid-weight-loss-drug-frenzy/?sh=9d6e9696a0ff This will be Europe's Nvidia in 2026. If you havent added shares to your PF yet, what are you waiting for?","The worst of the potential side effects, like pancreatitis, are largely already correlated with rapid weight loss, so I'm not even sure they are drug specific side effects.",1,0.528,NEGATIVE,1.0
